NKGNW
NKGen Biotech, Inc. Warrants
NASDAQ · Healthcare · Biotechnology · US
$0.03
+2408.33%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 652.0K | — | — | 77.0K | 426.0K |
| Cost of Revenue | 326.0K | — | — | 18.0K | 30.0K |
| Gross Profit | 326.0K | — | — | 59.0K | 396.0K |
| Operating Expenses | |||||
| R&D Expense | 9.6M | 10.7M | 15.7M | 16.7M | 14.7M |
| SG&A Expense | 14.8M | 16.3M | 14.1M | 7.7M | 7.6M |
| General & Admin Expense | 14.7M | 16.3M | 14.1M | 7.7M | 7.6M |
| Selling & Marketing Expense | 31.0K | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 24.3M | 27.0M | 29.7M | 24.4M | 22.3M |
| Cost and Expenses | 24.7M | — | 29.7M | 24.4M | 22.3M |
| Operating Income (EBIT) | (24.0M) | (27.0M) | (29.7M) | (24.3M) | (21.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 6.5M | 2.7M | 745.0K | 2.3M | 1.3M |
| Net Interest Income | 560.0K | (2.7M) | (745.0K) | (2.3M) | (1.3M) |
| Other Non-Op Income/Expense | 510.0K | (17.3M) | (53.2M) | (2.4M) | (1.4M) |
| Non-Operating Income (excl Interest) | (44.2M) | 14.5M | 52.5M | 95.0K | 84.0K |
| EBT (Pre-Tax Income) | (23.5M) | (44.2M) | (82.9M) | (26.7M) | (23.3M) |
| Income Tax Expense | 53.0K | 53.0K | 7.0K | 7.0K | 5.0K |
| Bottom Line | |||||
| Net Income | (23.6M) | (44.3M) | (83.0M) | (26.8M) | (23.3M) |
| Earnings from Cont. Ops | (23.6M) | (44.3M) | (83.0M) | (26.8M) | (23.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (43.0M) | (44.3M) | (83.0M) | (26.8M) | (23.3M) |
| Per Share | |||||
| Basic EPS | ($0.96) | ($1.54) | ($5.38) | ($1.25) | ($1.08) |
| Diluted EPS | ($1.33) | ($1.54) | ($5.38) | ($1.25) | ($1.08) |
| Revenue Per Share | $0.02 | $0.00 | $0.00 | $0.00 | $0.02 |
| Shares | |||||
| Basic Shares Outstanding | 28.8M | 28.8M | 15.4M | 21.5M | 21.5M |
| Diluted Shares Outstanding | 28.8M | 28.8M | 15.4M | 21.5M | 21.5M |
| Profitability Metrics | |||||
| EBITDA | (6.7M) | (27.0M) | (81.0M) | (23.2M) | (20.7M) |
| D&A | 53.0K | — | 1.2M | 1.2M | 1.2M |
| EBIT | 20.2M | (41.5M) | (82.2M) | (24.4M) | (21.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2025